Supplementary Material for: Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
datasetposted on 21.06.2016 by Barroso-Sousa R., Shapiro G.I., Tolaney S.M.
Datasets usually provide raw data for analysis. This raw data often comes in spreadsheet form, but can be any collection of data, on which analysis can be performed.
Clinical and preclinical data support a significant role for
inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6
in the treatment of patients with breast cancer. Recently,
based on data showing improvement in progression-free
survival, the use of palbociclib (Ibrance; Pfizer, Inc.) in
combination with endocrine agents was approved to
treat patients with hormone receptor-positive advanced
disease. Importantly, 2 other CDK4/6 inhibitors, abemaciclib
(LY2835219; Lilly) and ribociclib (LEE011; Novartis),
are in the late stage of clinical development. In this review,
we will focus on clinical data on these 2 new drugs,
highlighting their differences compared to palbociclib in
terms of single-agent activity, central nervous system
penetration, and common adverse events. In addition,
we will present the ongoing clinical trials and discuss future
directions in the field.